Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An ADHD 6-year-old child ultrarapid metabolizer for CYP2D6.

Journal of clinical psychopharmacology - 1 Aug 2006

Bonnet-Brilhault Frédérique, Broly Frank, Blanc Romuald, Furet Yves, Barthélémy Catherine, Paintaud Gilles

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Attention Deficit Disorder with Hyperactivity
Share to Central Nervous System Stimulants
Share to Child
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Metabolic Clearance Rate

Share to Methylphenidate

Share to Time Factors

Source

Identifiers

PMID: 16855474
DOI: 10.1097/01.jcp.0000227352.52288.50

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An ADHD 6-year-old child ultrarapid metabolizer for CYP2D6.PMID 16855474Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for <scp>Cytochrome P450 (<i>CYP</i>)</scp><i>2D6</i> Genotype and Atomoxetine TherapySemantic proximity Read ↗

CYP450 2D6 and 2C19 genotypes in ADHD: not related with treatment resistance but with over-representation of 2C19 ultra-metabolizers.Semantic proximity Read ↗

Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.Semantic proximity Read ↗

CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.Semantic proximity Read ↗

Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6.Semantic proximity Read ↗

Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together.Semantic proximity Read ↗

CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.Semantic proximity Read ↗

Evidence for Pharmacogenomic Effects on Risperidone Outcomes in Pediatrics.Semantic proximity Read ↗

A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence.Semantic proximity Read ↗

[Pharmaco-resistance and side effects of antipsychotics associated with poor metabolizer phenotype for cytochrome P450 2D6 in a context of early-onset schizophrenia: A case report].Semantic proximity Read ↗

Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity.Semantic proximity Read ↗

Personalizing Atomoxetine Dosing in Children with ADHD: What Can We Learn from Current Supporting EvidenceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.